Umbilical Cord and Maternal Blood Concentrations of Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 in Pregnancy Complicated by Preterm Premature Rupture of the Membranes and Histological Chorioamnionitis
Conditions: Preterm Premature Rupture of Membranes
Sponsor: Cengiz Gokcek Women's and Children's Hospital

Full study protocol and statistical 
analysis plan 
Official Title of the study: 
Umbilical cord and maternal blood concentrations of melatonin, soluble urokinase-type 
plasminogen activator receptor, and orosomucoid 2 in pregnancy complicated by preterm 
premature rupture of the membranes and histological chorioamnionitis 
 
Date of the document: 
October 2020. 
Contents: 
1. Participant Flow 
2. Baseline Characteristics 
3. Outcome Measures 
4.Endpoints of the study 
5.Limitations and Strengths 
6. Certain Agreements 
7. Results Point of Contact  
 
1. Participant Flow 
Recruitment Details 
This observational case-control study will be conducted at the Department of Obstetrics and 
Gynecology, Cengiz Gokcek Public Hospital, Gaziantep, Turkey, between October 2020 and 
October 2021. The protocol was approved by the Ethics Committee for Clinical Research of 
Gaziantep University (reference no: 2020/276). The study strictly will be adhered to the 
principles of the Declaration of Helsinki. All subjects will be included in the study gave oral 
and written informed consent. 88 women were enrolled in the study in two groups.  
Pre‐assignment Details 
The authors first will be assessed the recruited people to ensure meeting the inclusion and 
exclusion criteria. The inclusion criteria will be made according to the official documents. 
Arm/Group Information * 

 
There are two groups in the study. 
 
Arm/Group Title * 
 
preterm premature rupture of membranes group 
Control group 
2. Baseline Characteristics 
To detect significant difference between groups according to lead levels with a moderate 
effect size (Cohen's d =1), minimum required sample size was estimated as 44 for each group 
(α=0.05, 1-β=0.80). Power analysis was performed by using G power package version 3.1. 
Kolmogorov Smirnov and Shapiro Wilk tests will be used to test the normal distribution of 
data. For comparing groups (PPROM/control) the student t-test will be used for variables that 
have a normal distribution, and the Mann Whitney U test will be used for variables that have 
not a normal distribution. The ROC analysis will be applied for the determination of cut-off 
point for variables. Moreover, Spearman correlation test will be used for the relationship of 
between variables. SPSS for Windows 22.0 and Medcalc programs will be used for statistical 
analysis. p<0.05 will be accepted as statistical significance.  
 
3. Outcome Measures 
 
Primary Outcome Measures: melatonin, soluble urokinase-type plasminogen activator 
receptor, and orosomucoid 2 concentrations  
Secondary Outcome Measures: composite neonatal outcome (infant weight at delivery, 
neonatal intensive care unit hospitalization, and APGAR scores etc.)  
Tertiary Outcome Measures: obstetric ultrasound examination and fetal-maternal assessment 
 
 
4. Endpoints of the study:  
The primary outcome in these analyses will compare maternal serum melatonin, soluble 
urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements levels in 
study group and control group. 
 
5.Limitations and strengths: 

There will strengths of this study. The women participating in the study will recruit not 
received any treatment for PPROM at admission.  
6. Certain Agreements 
 
The authors declare that they have no conflict of interest. 
7. Results Point of Contact 
Corresponding Author: Ali Ovayolu, Department of Obstetrics and Gynecology, Cengiz 
Gokcek Women's and Children's Hospital, Gaziantep, Turkey, drovayolu@yahoo.com 
Address: Osmangazi Mahallesi, Cengiz Gokcek Kadın Hastaliklari ve Dogum Hastanesi, 
27010 Gaziantep, Turkey 
GSM: +90 (532) 640 40 60 
Tel.: +90.342 360 08 88 
Fax: +90.342 360 02 90